Small intestinal bacterial overgrowth
|Small intestine bacterial overgrowth syndrome|
|Classification and external resources|
Small intestinal bacterial overgrowth (SIBO), also termed bacterial overgrowth, or Small bowel bacterial overgrowth syndrome (SBBOS), is a disorder of excessive bacterial growth in the small intestine. Unlike the colon (or large bowel), which is rich with bacteria, the small bowel usually has fewer than 104 organisms per millilitre. Patients with bacterial overgrowth typically develop symptoms including nausea, bloating, vomiting, diarrhea, malnutrition, weight loss and malabsorption which is caused by a number of mechanisms.
The diagnosis of bacterial overgrowth is made by a number of techniques, with the gold standard diagnosis being an aspirate from the jejunum that grows in excess of 105 bacteria per millilitre. Risk factors for the development of bacterial overgrowth include dysmotility, anatomical disturbances in the bowel, including fistulae, diverticula and blind loops created after surgery, and resection of the ileo-cecal valve, gastroenteritis induced alterations to the small intestine as well as the use of certain medications, including proton pump inhibitors. Small bowel bacterial overgrowth syndrome is treated with an elemental diet or else antibiotics, which may be given in a cyclic fashion to prevent tolerance to the antibiotics sometimes followed by prokinetic drugs to prevent recurrence if dysmotility is a suspected cause.
Signs and symptoms
Bacterial overgrowth can cause a variety of symptoms, many of which are also found in other conditions, making the diagnosis challenging at times. Many of the symptoms are due to malabsorption of nutrients due to the effects of bacteria which either metabolize nutrients or cause inflammation of the small bowel impairing absorption. The symptoms of bacterial overgrowth include nausea, flatus, constipation, bloating, abdominal distension, abdominal pain or discomfort, diarrhea, fatigue, and weakness. SIBO also causes an increased permeability of the small intestine. Some patients may lose weight. Children with bacterial overgrowth may develop malnutrition and have difficulty attaining proper growth. Steatorrhea, a sticky type of diarrhea where fats are not properly absorbed and spill into the stool, may also occur.
Patients with bacterial overgrowth that is longstanding can develop complications of their illness as a result of malabsorption of nutrients. Anemia may occur from a variety of mechanisms, as many of the nutrients involved in production of red blood cells are absorbed in the affected small bowel. Iron is absorbed in the more proximal parts of the small bowel, the duodenum and jejunum, and patients with malabsorption of iron can develop a microcytic anemia, with small red blood cells. Vitamin B12 is absorbed in the last part of the small bowel, the ileum, and patients who malabsorb vitamin B12 can develop a megaloblastic anemia with large red blood cells. In older adults, small bowel bacterial overgrowth is associated with a higher frequency of diarrhea, a lower body mass index, and a significantly lower serum albumin concentration.
Certain species of bacteria are more commonly found in aspirates of the jejunum taken from patients with bacterial overgrowth. The most common isolates are Escherichia coli, Streptococcus, Lactobacillus, Bacteroides, and Enterococcus species.
Soon after birth, the gastrointestinal tract is colonized with bacteria, which, on the basis of models with animals raised in a germ-free environment, have beneficial effects on function of the gastrointestinal tract. There are 500-1000 different species of bacteria that reside in the bowel. However, if the flora of the small bowel is altered, inflammation or altered digestion can occur, leading to symptoms. Many patients with chronic diarrhea have bacterial overgrowth as a cause or a contributor to their symptoms.
While the consensus definition of chronic diarrhea varies, in general it is considered to be an alteration in stool consistency or increased frequency, that occurs for over three weeks. Various mechanisms are involved in the development of diarrhea in bacterial overgrowth. First, the excessive bacterial concentrations can cause direct inflammation of the small bowel cells, leading to an inflammatory diarrhea. The malabsorption of lipids, proteins and carbohydrates may cause poorly digestible products to enter into the colon. This can cause diarrhea by the osmotic drive of these molecules, but can also stimulate the secretory mechanisms of colonic cells, leading to a secretory diarrhea.
There is an overlap in findings between tropical sprue, post-infectious irritable bowel syndrome and small intestinal bacterial overgrowth in the pathophysiology of the three conditions and also SIBO can similarly sometimes be triggered by an acute gastrointestinal infection.
Risk factors and causes
Certain patients are more predisposed to the development of bacterial overgrowth because of certain risk factors. These factors can be grouped into three categories: (1) disordered motility or movement of the small bowel or anatomical changes that lead to stasis, (2) disorders in the immune system and (3) conditions that cause more bacteria from the colon to enter the small bowel.
Problems with motility may either be diffuse, or localized to particular areas. Diseases like scleroderma and possibly celiac disease cause diffuse slowing of the bowel, leading to increased bacterial concentrations. More commonly, the small bowel may have anatomical problems, such as out-pouchings known as diverticula that can cause bacteria to accumulate. After surgery involving the stomach and duodenum (most commonly with Billroth II antrectomy), a blind loop may be formed, leading to stasis of flow of intestinal contents. This can cause overgrowth, and is termed blind loop syndrome.
Disorders of the immune system can cause bacterial overgrowth. Chronic pancreatitis, or inflammation of the pancreas can cause bacterial overgrowth through mechanisms linked to this. The use of immunosuppressant medications to treat other conditions can cause this, as evidenced from animal models. Other causes include inherited immunodeficiency conditions, such as combined variable immunodeficiency, IgA deficiency, and hypogammaglobulinemia.
Finally, abnormal connections between the bacteria-rich colon and the small bowel can increase the bacterial load in the small bowel. Patients with Crohn's disease or other diseases of the ileum may require surgery that removes the ileocecal valve connecting the small and large bowel; this leads to an increased reflux of bacteria into the small bowel. After bariatric surgery for obesity, connections between the stomach and the ileum can be formed, which may increase bacterial load in the small bowel.
In recent years, several proposed links between SIBO and other disorders have been made. However, the usual methodology of these studies involves the use of breath testing as an indirect investigation for SIBO. Breath testing has been criticized by some authors for being an imperfect test for SIBO, with multiple known false positives.
Some studies reported up to 80% of patients with irritable bowel syndrome (IBS) have SIBO (using the hydrogen breath test). Subsequent studies demonstrated statistically significant reduction in IBS symptoms following therapy for SIBO.
There is a lack of consensus however, regarding the suggested link between IBS and SIBO. Other authors concluded that the abnormal breath results so common in IBS patients do not suggest SIBO, and state that "abnormal fermentation timing and dynamics of the breath test findings support a role for abnormal intestinal bacterial distribution in IBS."  There is general consensus that breath tests are abnormal in IBS, however the disagreement lies in whether this is representative of SIBO. More research is needed to clarifiy this possible link.
Fibromyalgia is a poorly understood pain condition. Lactulose breath testing has shown that patients with fibromyalgia have a more pronounced degree of abnormal results compared to both IBS patients and the general population. This study also demonstrated positive correlation between the amount of pain and the degree of abnormality on the breath test. A subsequent study also demonstrated increased prevalence of intestinal hyperpermeability, which some believe occurs commonly with SIBO.
Intestinal bacteria may play an etiological role in the dermatological condition Rosacea. A recent study subjected patients to a hydrogen breath test to detect the occurrence of SIBO. It was found that significantly more patients were hydrogen-positive than controls indicating the presence of bacterial overgrowth (47% v. 5%, p<0.001).
Hydrogen-positive patients were then given a 10-day course of rifaximin, a non-absorbable antibiotic that does not leave the digestive tract and therefore does not enter the circulation or reach the skin. 96% of patients experienced a complete remission of rosacea symptoms that lasted beyond 9 months. These patients were also negative when retested for bacterial overgrowth. In the 4% of patients that experienced relapse, it was found that bacterial overgrowth had returned. These patients were given a second course of rifaximin which again cleared rosacea symptoms and normalized hydrogen excretion.
In another study, it was found that some rosacea patients that tested hydrogen-negative were still positive for bacterial overgrowth when using a methane breath test instead. These patients showed little improvement with rifaximin, as found in the previous study, but experienced clearance of rosacea symptoms and normalization of methane excretion following administration of the antibiotic metronidazole, which is effective at targeting methanogenic intestinal bacteria.
These results suggest that optimal antibiotic therapy may vary between patients and that diverse species of intestinal bacteria appear to be capable of mediating rosacea symptoms.
This may also explain the improvement in symptoms experienced by some patients when given a reduced carbohydrate diet. Such a diet would restrict the available material necessary for bacterial fermentation and thereby reduce intestinal bacterial populations.
The diagnosis of bacterial overgrowth can be made by physicians in various ways. Malabsorption can be detected by a test called the D-xylose test. Xylose is a sugar that does not require enzymes to be digested. The D-xylose test involves having a patient drink a certain quantity of D-xylose, and measuring levels in the urine and blood; if there is no evidence of D-xylose in the urine and blood, it suggests that the small bowel is not absorbing properly (as opposed to problems with enzymes required for digestion).
The gold standard for detection of bacterial overgrowth is the aspiration of more than 105 bacteria per millilitre from the small bowel. The normal small bowel has less than 104 bacteria per millilitre. Some experts however, consider aspiration of more than 103 positive if the flora is predominately colonic type bacteria as these types of bacteria are considered pathological in excessive numbers in the small intestine. The reliability of aspiration in the diagnosis of SIBO has been questioned as SIBO can be patchy and the reproducibility can be as low as 38 percent. Breath tests have their own reliability problems with a high rate of false positive. Some doctors factor in a patients' response to treatment as part of the diagnosis.
Breath tests have been developed to test for bacterial overgrowth, based on bacterial metabolism of carbohydrates to hydrogen and/or methane, or based on the detection of by-products of digestion of carbohydrates that are not usually metabolized. The hydrogen breath test involves having the patient fast for a minimum of 12 hours then having them drink a substrate usually glucose or lactulose, then measuring expired hydrogen and methane concentrations typically over a period of 2–3 hours. It compares well to jejunal aspirates in making the diagnosis of bacterial overgrowth. 13C and 14C based tests have also been developed based on the bacterial metabolism of D-xylose. Increased bacterial concentrations are also involved in the deconjugation of bile acids. The glycocholic acid breath test involves the administration of the bile acid 14C glychocholic acid, and the detection of 14CO2, which would be elevated in bacterial overgrowth.
Some patients with symptoms of bacterial overgrowth will undergo gastroscopy, or visualization of the stomach and duodenum with an endoscopic camera. Biopsies of the small bowel in bacterial overgrowth can mimic those of celiac disease, making the diagnosis more challenging. Findings include blunting of villi, hyperplasia of crypts and an increased number of lymphocytes in the lamina propria.
However, some physicians suggest that if the suspicion of bacterial overgrowth is high enough, the best diagnostic test is a trial of treatment. If the symptoms improve, an empiric diagnosis of bacterial overgrowth can be made.
Bacterial overgrowth is usually treated with a course of antibiotics although whether antibiotics should be a first line treatment is a matter of debate. Some experts recommend probiotics as first line therapy with antibiotics being reserved as a second line treatment for more severe cases of SIBO. Prokinetic drugs are other options but research in humans is limited. A variety of antibiotics, including tetracycline, amoxicillin-clavulanate, fluoroquinolones, metronidazole, neomycin, cephalexin, trimethoprim-sulfamethoxazole, and nitazoxanide have been used; however, the best evidence is for the use of rifaximin.
A course of one week of antibiotics is usually sufficient to treat the condition. However, if the condition recurs, antibiotics can be given in a cyclical fashion in order to prevent tolerance. For example, antibiotics may be given for a week, followed by three weeks off antibiotics, followed by another week of treatment. Alternatively, the choice of antibiotic used can be cycled.
The condition that predisposed the patient to bacterial overgrowth should also be treated. For example, if the bacterial overgrowth is caused by chronic pancreatitis, the patient should be treated with coated pancreatic enzyme supplements.
Probiotics are bacterial preparations that alter the bacterial flora in the bowel to cause a beneficial effect. Animal research has demonstrated that probiotics have barrier enhancing, antibacterial, immune modulating and anti-inflammatory effects which may have a positive effect in the management of SIBO in humans. Lactobacillus casei has been found to be effective in improving breath hydrogen scores after 6 weeks of treatment presumably by suppressing levels of a small intestinal bacterial overgrowth of fermenting bacteria. The multi-strain preparation VSL#3 was found to be effective in suppressing SIBO. Lactobacillus plantarum, lactobacillus acidophilus, lactobacillus casei have all demonstrated effectiveness in the treatment and management of SIBO. Conversely lactobacillus fermentum and saccharomyces boulardii have been found to be ineffective. A combination of lactobacillus plantarum and lactobacillus rhamnosus has been found to be effective in suppressing bacterial overgrowth of abnormal gas producing organisms in the small intestine. Probiotics are superior to antibiotics in the treatment of SIBO. A combination of probiotic strains has been found to produce better results than therapy with the antibiotic drug metronidazole and probiotics have been found to be effective in treating and preventing secondary lactase deficiency and small intestinal bacteria overgrowth in individuals suffering from post-infectious irritable bowel syndrome. Probiotics taken in uncomplicated cases of SIBO can usually result in the individual becoming symptom free. Probiotic therapy may need to be taken continuously to prevent the return of overgrowth of gas producing bacteria. Probiotic yogurt may also be effective in treating SIBO with evidence of reduced inflammation after 4 weeks of treatment.
An elemental diet taken for two weeks is an alternative to antibiotics for eliminating SIBO. An elemental diet works via providing nutrition for the individual while depriving the bacteria of a food source. Additional treatment options include the use of prokinetic drugs such as 5-HT4 receptor agonists or motilin agonists to extend the SIBO free period after treatment with an elemental diet or antibiotics. A diet void of certain foods that feed the bacteria can help alleviate the symptoms. For example if the symptoms are caused by bacterial overgrowth feeding on indigestible carbohydrate rich foods, following a FODMAP restriction diet may help.
- Quigley E, Quera R (2006). "Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics". Gastroenterology 130 (2 Suppl 1): S78–90. doi:10.1053/j.gastro.2005.11.046. PMID 16473077.
- Bures, J; Cyrany, J; Kohoutova, D; Förstl, M; Rejchrt, S; Kvetina, J; Vorisek, V; Kopacova, M (Jun 28, 2010). "Small intestinal bacterial overgrowth syndrome.". World journal of gastroenterology : WJG 16 (24): 2978–90. doi:10.3748/wjg.v16.i24.2978. PMC 2890937. PMID 20572300.
- Teo M, Chung S, Chitti L, Tran C, Kritas S, Butler R, Cummins A (2004). "Small bowel bacterial overgrowth is a common cause of chronic diarrhea". J Gastroenterol Hepatol 19 (8): 904–9. doi:10.1111/j.1440-1746.2004.03376.x. PMID 15242494.
- Kirsch M (1990). "Bacterial overgrowth". Am J Gastroenterol 85 (3): 231–7. PMID 2178395.
- Lin, HC. (Aug 2004). "Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome". JAMA 292 (7): 852–8. doi:10.1001/jama.292.7.852. PMID 15316000.
- Sachdev, AH.; Pimentel, M. (Sep 2013). "Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance". Ther Adv Chronic Dis 4 (5): 223–31. doi:10.1177/2040622313496126. PMID 23997926.
- Lykova EA, Bondarenko VM, Parfenov AI, Matsulevich TV (2005). "[Bacterial overgrowth syndrome in the small intestine: pathogenesis, clinical significance and therapy tactics]". Eksp Klin Gastroenterol (in Russian) (6): 51–7, 113. PMID 17378388.
- Parlesak, A; Klein, B; Schecher, K; Bode, JC; Bode, C (2003). "Prevalence of small bowel bacterial overgrowth and its association with nutrition intake in nonhospitalized older adults.". J Am Geriatrics Soc 51 (6): 768–773. doi:10.1046/j.1365-2389.2003.51259.x. PMID 12757562.
- Bouhnik Y, Alain S, Attar A, Flourié B, Raskine L, Sanson-Le Pors M, Rambaud J (1999). "Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome". Am J Gastroenterol 94 (5): 1327–31. doi:10.1111/j.1572-0241.1999.01016.x. PMID 10235214.
- Hao W, Lee Y (2004). "Microflora of the gastrointestinal tract: a review". Methods Mol Biol 268: 491–502. doi:10.1385/1-59259-766-1:491. ISBN 1-59259-766-1. PMID 15156063.
- Ghoshal, UC.; Park, H.; Gwee, KA. (Feb 2010). "Bugs and irritable bowel syndrome: The good, the bad and the ugly.". J Gastroenterol Hepatol 25 (2): 244–51. doi:10.1111/j.1440-1746.2009.06133.x. PMID 20074148.
- Othman, M.; Agüero, R.; Lin, HC. (Jan 2008). "Alterations in intestinal microbial flora and human disease.". Curr Opin Gastroenterol 24 (1): 11–6. doi:10.1097/MOG.0b013e3282f2b0d7. PMID 18043226.
- Rose S, Young M, Reynolds J (1998). "Gastrointestinal manifestations of scleroderma". Gastroenterol Clin North Am 27 (3): 563–94. doi:10.1016/S0889-8553(05)70021-2. PMID 9891698.
- Tursi A, Brandimarte G, Giorgetti G (2003). "High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal". Am J Gastroenterol 98 (4): 839–43. doi:10.1111/j.1572-0241.2003.07379.x. PMID 12738465.
- Kongara K, Soffer E (2000). "Intestinal motility in small bowel diverticulosis: a case report and review of the literature". J Clin Gastroenterol 30 (1): 84–6. doi:10.1097/00004836-200001000-00017. PMID 10636218.
- Isaacs P, Kim Y (1983). "Blind loop syndrome and small bowel bacterial contamination". Clin Gastroenterol 12 (2): 395–414. PMID 6347463.
- Trespi E, Ferrieri A (1999). "Intestinal bacterial overgrowth during chronic pancreatitis". Curr Med Res Opin 15 (1): 47–52. doi:10.1185/03007999909115173. PMID 10216811.
- Marshall J, Christou N, Meakins J (1988). "Small-bowel bacterial overgrowth and systemic immunosuppression in experimental peritonitis". Surgery 104 (2): 404–11. PMID 3041643.
- Pignata C, Budillon G, Monaco G, Nani E, Cuomo R, Parrilli G, Ciccimarra F (1990). "Jejunal bacterial overgrowth and intestinal permeability in children with immunodeficiency syndromes". Gut 31 (8): 879–82. doi:10.1136/gut.31.8.879. PMC 1378614. PMID 2387510.
- Kholoussy A, Yang Y, Bonacquisti K, Witkowski T, Takenaka K, Matsumoto T (1986). "The competence and bacteriologic effect of the telescoped intestinal valve after small bowel resection". Am Surg 52 (10): 555–9. PMID 3767143.
- Abell T, Minocha A (2006). "Gastrointestinal complications of bariatric surgery: diagnosis and therapy". Am J Med Sci 331 (4): 214–8. doi:10.1097/00000441-200604000-00008. PMID 16617237.
- Lo, WK.; Chan, WW. (May 2013). "Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis.". Clin Gastroenterol Hepatol 11 (5): 483–90. doi:10.1016/j.cgh.2012.12.011. PMID 23270866.
- Simrén, M; Stotzer, PO (March 2006). "Use and abuse of hydrogen breath tests.". Gut 55 (3): 297–303. doi:10.1136/gut.2005.075127. PMC 1856094. PMID 16474100.
- Pimentel, Mark (2006). A new IBS solution : bacteria, the missing link in treating irritable bowel syndrome. Sherman Oaks, CA: Health Point Press. ISBN 0977435601.
- Reddymasu, SC; Sostarich, S; McCallum, RW (Feb 22, 2010). "Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?". BMC gastroenterology 10: 23. doi:10.1186/1471-230X-10-23. PMC 2838757. PMID 20175924.
- Lin, HC (Aug 18, 2004). "Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome.". JAMA: the Journal of the American Medical Association 292 (7): 852–8. doi:10.1001/jama.292.7.852. PMID 15316000.
- Shah, ED; Basseri, RJ; Chong, K; Pimentel, M (September 2010). "Abnormal breath testing in IBS: a meta-analysis.". Digestive diseases and sciences 55 (9): 2441–9. doi:10.1007/s10620-010-1276-4. PMID 20467896.
- Ford, AC; Spiegel, BM; Talley, NJ; Moayyedi, P (December 2009). "Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis.". Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 7 (12): 1279–86. doi:10.1016/j.cgh.2009.06.031. PMID 19602448.
- Pimentel, M; Wallace, D; Hallegua, D; Chow, E; Kong, Y; Park, S; Lin, HC (April 2004). "A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing.". Annals of the rheumatic diseases 63 (4): 450–2. doi:10.1136/ard.2003.011502. PMC 1754959. PMID 15020342.
- Goebel, A; Buhner, S; Schedel, R; Lochs, H; Sprotte, G (August 2008). "Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome.". Rheumatology (Oxford, England) 47 (8): 1223–7. doi:10.1093/rheumatology/ken140. PMID 18540025.
- Parodi A,Paolino S,Greco A,Drago F,Mansi C,Rebora A,Parodi AU,Savarino V (May 2008). "Small Intestinal Bacterial Overgrowth in Rosacea: Clinical Effectiveness of Its Eradication". Clin Gastroenterol Hepatol. 6 (7): 759–64. doi:10.1016/j.cgh.2008.02.054. PMID 18456568.
- UEGW Vienna 2008 - 16th United European Gastroenterology Week
- Paton, E; Murray, E; Watson, WC (19 February 1966). "Intestinal Disaccharidase Activity in Rosacea". British Medical Journal 1 (5485): 459–460. doi:10.1136/bmj.1.5485.459. Retrieved 1 July 2013.
- Craig R, Atkinson A (1988). "D-xylose testing: a review". Gastroenterology 95 (1): 223–31. PMID 3286361.
- Corazza G, Menozzi M, Strocchi A, Rasciti L, Vaira D, Lecchini R, Avanzini P, Chezzi C, Gasbarrini G (1990). "The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing". Gastroenterology 98 (2): 302–9. PMID 2295385.
- Kerlin P, Wong L (1988). "Breath hydrogen testing in bacterial overgrowth of the small intestine". Gastroenterology 95 (4): 982–8. PMID 3410238.
- Donald I, Kitchingmam G, Donald F, Kupfer R (1992). "The diagnosis of small bowel bacterial overgrowth in elderly patients". J Am Geriatr Soc 40 (7): 692–6. PMID 1607585.
- Toskes P, Giannella R, Jervis H, Rout W, Takeuchi A (1975). "Small intestinal mucosal injury in the experimental blind loop syndrome. Light- and electron-microscopic and histochemical studies". Gastroenterology 68 (5 Pt 1): 1193–203. PMID 1126607.
- Singh VV, Toskes PP (2004). "Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment". Curr Treat Options Gastroenterol 7 (1): 19–28. doi:10.1007/s11938-004-0022-4. PMID 14723835.
- Goulet, O.; Joly, F. (Sep 2010). "[Intestinal microbiota in short bowel syndrome]". Gastroenterol Clin Biol. 34 Suppl 1: S37–43. doi:10.1016/S0399-8320(10)70019-1. PMID 20889003.
- Bondarenko VM, Lykova EA, Matsulevich TV (2006). "[Microecological aspects of small intestinal bacterial overgrowth syndrome]". Zh. Mikrobiol. Epidemiol. Immunobiol. (in Russian) (6): 57–63. PMID 17163142.
- Bures, J.; Cyrany, J.; Kohoutova, D.; Förstl, M.; Rejchrt, S.; Kvetina, J.; Vorisek, V.; Kopacova, M. (Jun 2010). "Small intestinal bacterial overgrowth syndrome". World J Gastroenterol 16 (24): 2978–90. doi:10.3748/wjg.v16.i24.2978. PMC 2890937. PMID 20572300.
- Barrett, JS.; Canale, KE.; Gearry, RB.; Irving, PM.; Gibson, PR. (Aug 2008). "Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome". World J Gastroenterol 14 (32): 5020–4. doi:10.3748/wjg.14.5020. PMC 2742929. PMID 18763284.
- Meier, R.; Burri, E.; Steuerwald, M. (Sep 2003). "The role of nutrition in diarrhoea syndromes". Curr Opin Clin Nutr Metab Care 6 (5): 563–7. doi:10.1097/01.mco.0000087972.83880.d3 (inactive 2014-03-24). PMID 12913674.
- Rolfe, RD. (Feb 2000). "The role of probiotic cultures in the control of gastrointestinal health". J Nutr 130 (2S Suppl): 396S–402S. PMID 10721914.
- Bested, AC.; Logan, AC.; Selhub, EM. (2013). "Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: part III - convergence toward clinical trials". Gut Pathog 5 (1): 4. doi:10.1186/1757-4749-5-4. PMC 3605358. PMID 23497650.
- Shcherbakova, PL.; Parfenov, AI.; Ruchkina, IN.; Fadeeva, NA.; Gubina, AV.; Melik-Agadzhanian, NB.; Poleva, NI.; Khomeriki, SG.; Chikunova, BZ. (2012). "[Lactase deficiency in patients with postinfectious irritable bowel syndrome and the role of intestinal microflora in its development]". Eksp Klin Gastroenterol (5): 91–8. PMID 23402179.
- Hamvas, J. (Aug 2012). "[Proton-pump inhibitor therapy and small bowel bacterial contamination]". Orv Hetil 153 (33): 1287–93. doi:10.1556/OH.2012.29419. PMID 22890175.
- Gaon, D.; Garmendia, C.; Murrielo, NO.; de Cucco Games, A.; Cerchio, A.; Quintas, R.; González, SN.; Oliver, G. (2002). "Effect of Lactobacillus strains (L. casei and L. Acidophillus Strains cerela) on bacterial overgrowth-related chronic diarrhea". Medicina (B Aires) 62 (2): 159–63. PMID 12038039.
- Schiffrin, EJ.; Parlesak, A.; Bode, C.; Bode, JC.; van't Hof, MA.; Grathwohl, D.; Guigoz, Y. (Apr 2009). "Probiotic yogurt in the elderly with intestinal bacterial overgrowth: endotoxaemia and innate immune functions" (PDF). Br J Nutr 101 (7): 961–6. doi:10.1017/s0007114508055591. PMID 19353762.
- Buchman, Alan. (2006). Clinical nutrition in gastrointestinal diseas. Thorofare, NJ: SLACK. p. 277. ISBN 978-1-55642-697-1.
- Talley, Nicholas Joseph.; Kane, Sunanda.; Wallace, Michael B. (Michael Bradley) (2010). Practical Gastroenterology and Hepatology: Small and Large Intestine and Pancreas. Chichester, West Sussex: Wiley-Blackwell. ISBN 978-1-4051-8274-4.
- Gibson, PR.; Barrett, JS. (2010). "The concept of small intestinal bacterial overgrowth in relation to functional gastrointestinal disorders". Nutrition 26 (11–12): 1038–43. doi:10.1016/j.nut.2010.01.005. PMID 20418060.